Eli Lilly and Company (NYSE:LLY) is one of the 15 best stocks to invest in for an 18 year old. UBS kept its Buy rating and $1 ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...